Joseph has made over 1 trades of the ThermoGenesis Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 35,000 units of THMO stock worth $6,300 on 28 August 2018.
The largest trade he's ever made was buying 35,000 units of ThermoGenesis Inc stock on 28 August 2018 worth over $6,300. On average, Joseph trades about 5,000 units every 0 days since 2017. As of 28 August 2018 he still owns at least 35,000 units of ThermoGenesis Inc stock.
You can see the complete history of Joseph Joseph stock trades at the bottom of the page.
Dr. Joseph Thomis Ph.D. serves as Independent Director of the Company. Dr. Thomis joined our Board in January 2017. Since 2012 Dr. Thomis has been the CEO at Thomis Consulting BVBA and a partner in OxOnc Development LP, an oncology product development company. From 1997-2012 he was employed at Quintiles Transnational where he held numerous positions including Chairman of the American Management Board, President of Global Clinical Development Services and President of European Clinical Development Services. Dr. Thomis has served as a non-executive director at NovaQuest LLC, a private equity company, since 2014, and is a member of the Audit Committee and Chairman of the Board of Quotient Clinical, a translational pharmaceutics company, since 2016. From 2013-2015, he served as Chairman of the Board of Idis Pharma, a global company providing unlicensed medicines to patients with unmet medical needs. From 2012 to 2013 Dr. Thomis was a non-executive director of PDP Courier Services, Ltd and from 2010-2012 he was Chairman of the American Management Board of Quintiles. Dr. Thomis received his Ph.D. in Pharmaceutical Sciences from the University of Leuven in Belgium. Thomis is well qualified to serve as a director due to his extensive experience with clinical trials and contract research organizations, and we believe that Dr. Thomis will be a valuable asset to the Company and its Board by providing valuable insight and knowledge with respect to the Company’s clinical development activities. Dr. Thomis is one of our independent directors pursuant to applicable NASDAQ rules.
Joseph Thomis is 74, he's been the Independent Director of ThermoGenesis Inc since 2017. There are 1 older and 9 younger executives at ThermoGenesis Inc. The oldest executive at ThermoGenesis Holdings Inc is Philip H. Coelho, 77, who is the Chief Technology Officer.
Thomis's mailing address filed with the SEC is 2711, Citrus Road, Rancho Cordova, Sacramento County, California, 95742, United States of America.
Over the last 5 years, insiders at ThermoGenesis Inc have traded over $612,000 worth of ThermoGenesis Inc stock. The most active insiders traders include Xiaochun Boyalife Group, In... et Thomis Joseph. On average, ThermoGenesis Inc executives and independent directors trade stock every 0 days with the average trade being worth of $120,000. The most recent stock trade was executed by Xiaochun Boyalife Group, In... on 17 November 2023, trading 600,000 units of THMO stock currently worth $612,000.
thermogenesis holdings, inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (car)-t and other cell-based therapies. it markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed car-txpress platform, which streamlines the manufacturing process for the emerging car-t immunotherapy market. the company operates through two segments, device and clinical development. it manufactures and markets products for clinical bio-banking applications, including axp automated cell separation system, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and bioarchive automated cryopreservation system, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical appli
ThermoGenesis Inc executives and other stock owners filed with the SEC include: